Cargando…

Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study

BACKGROUND: HMS5552, a novel fourth-generation glucokinase (GK) activator, has demonstrated promising effects on glycemic control in preclinical models of type 2 diabetes. This single ascending dose study was conducted to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynam...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Hongrong, Sheng, Lei, Chen, Weili, Yuan, Fei, Yang, Mengjie, Li, Hui, Li, Xuening, Choi, John, Zhao, Guiyu, Hu, Tianxin, Li, Yongguo, Zhang, Yi, Chen, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869670/
https://www.ncbi.nlm.nih.gov/pubmed/27274195
http://dx.doi.org/10.2147/DDDT.S105021
_version_ 1782432359488946176
author Xu, Hongrong
Sheng, Lei
Chen, Weili
Yuan, Fei
Yang, Mengjie
Li, Hui
Li, Xuening
Choi, John
Zhao, Guiyu
Hu, Tianxin
Li, Yongguo
Zhang, Yi
Chen, Li
author_facet Xu, Hongrong
Sheng, Lei
Chen, Weili
Yuan, Fei
Yang, Mengjie
Li, Hui
Li, Xuening
Choi, John
Zhao, Guiyu
Hu, Tianxin
Li, Yongguo
Zhang, Yi
Chen, Li
author_sort Xu, Hongrong
collection PubMed
description BACKGROUND: HMS5552, a novel fourth-generation glucokinase (GK) activator, has demonstrated promising effects on glycemic control in preclinical models of type 2 diabetes. This single ascending dose study was conducted to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HMS5552 during its first-in-human exposure. METHODS: Sixty healthy subjects were enrolled. In each of six dose-cohorts (5, 10, 15, 25, 35, and 50 mg), ten subjects were randomized with eight subjects receiving the same cohort-dose of HMS5552 and two receiving placebo. Plasma HMS5552 exposure, glucose, and insulin were measured repeatedly during fasting and after a standardized meal. Assessment included safety, PK, and PD endpoints. RESULTS: HMS5552 showed dose-proportional increases in area under the curve 0 to the last quantifiable concentration (AUC(0–t)) and maximum plasma concentration (C(max)). Slopes estimated by linear regression for AUC(0–t) and C(max) were ~1.0 (0.932 and 0.933, respectively). Geometric mean elimination half-life ranged from 4.48 to 7.51 hours and apparent clearance ranged from 11.5 to 13.1 L/h across all doses. No significant sex effect was observed in PK parameters. HMS5552 also demonstrated dose-related PD responses in terms of maximum glucose change from baseline (%) and mean glucose area under effect curve 0–4 hours change from baseline (%) (P<0.001). Fifteen adverse events were reported by nine subjects (ten with HMS5552 and five with the placebo). All adverse events were mild in intensity and resolved without any treatment. CONCLUSION: This first-in-human single ascending dose study provided predicted PK of HMS5552 with dose-proportional increases in AUC(0–t) and C(max), as well as dose-related glucose-lowering effects over the range of 5–50 mg in healthy subjects. HMS5552 at doses up to 50 mg in healthy subjects was safe and well-tolerated.
format Online
Article
Text
id pubmed-4869670
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48696702016-06-07 Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study Xu, Hongrong Sheng, Lei Chen, Weili Yuan, Fei Yang, Mengjie Li, Hui Li, Xuening Choi, John Zhao, Guiyu Hu, Tianxin Li, Yongguo Zhang, Yi Chen, Li Drug Des Devel Ther Original Research BACKGROUND: HMS5552, a novel fourth-generation glucokinase (GK) activator, has demonstrated promising effects on glycemic control in preclinical models of type 2 diabetes. This single ascending dose study was conducted to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HMS5552 during its first-in-human exposure. METHODS: Sixty healthy subjects were enrolled. In each of six dose-cohorts (5, 10, 15, 25, 35, and 50 mg), ten subjects were randomized with eight subjects receiving the same cohort-dose of HMS5552 and two receiving placebo. Plasma HMS5552 exposure, glucose, and insulin were measured repeatedly during fasting and after a standardized meal. Assessment included safety, PK, and PD endpoints. RESULTS: HMS5552 showed dose-proportional increases in area under the curve 0 to the last quantifiable concentration (AUC(0–t)) and maximum plasma concentration (C(max)). Slopes estimated by linear regression for AUC(0–t) and C(max) were ~1.0 (0.932 and 0.933, respectively). Geometric mean elimination half-life ranged from 4.48 to 7.51 hours and apparent clearance ranged from 11.5 to 13.1 L/h across all doses. No significant sex effect was observed in PK parameters. HMS5552 also demonstrated dose-related PD responses in terms of maximum glucose change from baseline (%) and mean glucose area under effect curve 0–4 hours change from baseline (%) (P<0.001). Fifteen adverse events were reported by nine subjects (ten with HMS5552 and five with the placebo). All adverse events were mild in intensity and resolved without any treatment. CONCLUSION: This first-in-human single ascending dose study provided predicted PK of HMS5552 with dose-proportional increases in AUC(0–t) and C(max), as well as dose-related glucose-lowering effects over the range of 5–50 mg in healthy subjects. HMS5552 at doses up to 50 mg in healthy subjects was safe and well-tolerated. Dove Medical Press 2016-05-09 /pmc/articles/PMC4869670/ /pubmed/27274195 http://dx.doi.org/10.2147/DDDT.S105021 Text en © 2016 Xu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Xu, Hongrong
Sheng, Lei
Chen, Weili
Yuan, Fei
Yang, Mengjie
Li, Hui
Li, Xuening
Choi, John
Zhao, Guiyu
Hu, Tianxin
Li, Yongguo
Zhang, Yi
Chen, Li
Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
title Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
title_full Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
title_fullStr Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
title_full_unstemmed Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
title_short Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
title_sort safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator hms5552: results from a first-in-human single ascending dose study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869670/
https://www.ncbi.nlm.nih.gov/pubmed/27274195
http://dx.doi.org/10.2147/DDDT.S105021
work_keys_str_mv AT xuhongrong safetytolerabilitypharmacokineticsandpharmacodynamicsofnovelglucokinaseactivatorhms5552resultsfromafirstinhumansingleascendingdosestudy
AT shenglei safetytolerabilitypharmacokineticsandpharmacodynamicsofnovelglucokinaseactivatorhms5552resultsfromafirstinhumansingleascendingdosestudy
AT chenweili safetytolerabilitypharmacokineticsandpharmacodynamicsofnovelglucokinaseactivatorhms5552resultsfromafirstinhumansingleascendingdosestudy
AT yuanfei safetytolerabilitypharmacokineticsandpharmacodynamicsofnovelglucokinaseactivatorhms5552resultsfromafirstinhumansingleascendingdosestudy
AT yangmengjie safetytolerabilitypharmacokineticsandpharmacodynamicsofnovelglucokinaseactivatorhms5552resultsfromafirstinhumansingleascendingdosestudy
AT lihui safetytolerabilitypharmacokineticsandpharmacodynamicsofnovelglucokinaseactivatorhms5552resultsfromafirstinhumansingleascendingdosestudy
AT lixuening safetytolerabilitypharmacokineticsandpharmacodynamicsofnovelglucokinaseactivatorhms5552resultsfromafirstinhumansingleascendingdosestudy
AT choijohn safetytolerabilitypharmacokineticsandpharmacodynamicsofnovelglucokinaseactivatorhms5552resultsfromafirstinhumansingleascendingdosestudy
AT zhaoguiyu safetytolerabilitypharmacokineticsandpharmacodynamicsofnovelglucokinaseactivatorhms5552resultsfromafirstinhumansingleascendingdosestudy
AT hutianxin safetytolerabilitypharmacokineticsandpharmacodynamicsofnovelglucokinaseactivatorhms5552resultsfromafirstinhumansingleascendingdosestudy
AT liyongguo safetytolerabilitypharmacokineticsandpharmacodynamicsofnovelglucokinaseactivatorhms5552resultsfromafirstinhumansingleascendingdosestudy
AT zhangyi safetytolerabilitypharmacokineticsandpharmacodynamicsofnovelglucokinaseactivatorhms5552resultsfromafirstinhumansingleascendingdosestudy
AT chenli safetytolerabilitypharmacokineticsandpharmacodynamicsofnovelglucokinaseactivatorhms5552resultsfromafirstinhumansingleascendingdosestudy